Brian Tinmouth
Vermogen: 49 349 $ op 30-06-2026
Vermogen: 49 349 $ op 30-06-2026
Brian Philippe Tinmouth is currently an Independent Director at SCYNEXIS, Inc. since 2019.
Formerly, Mr. Tinmouth was Chief Business & Strategy Officer at Mammoth Biosciences, Inc. from 2022 to 2025, Chief Business & Strategy Officer at Pardes Biosciences, Inc. from 2021 to 2022, Vice President & Head-Business Development at Vertex Pharmaceuticals, Inc. from 2013 to 2020, and Senior Manager at Bain & Co., Inc. from 1997 to 2002.
Mr. Tinmouth completed undergraduate studies at Queen's University and earned an MBA from Harvard Business School.
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SCYNEXIS, INC. 0,12% | 26-06-2026 | 12.125 ( 0,12% ) | 49 349 $ | 30-06-2026 |
| Bedrijven | Functie | Begin |
|---|---|---|
| SCYNEXIS, INC. | Directeur/Bestuurslid | 13-12-2019 |
| Bedrijven | Functie | Einde |
|---|---|---|
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Corporate Officer/Principal | 01-02-2025 |
| PARDES BIOSCIENCES, INC. | Corporate Officer/Principal | 30-11-2022 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01-03-2020 |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Corporate Officer/Principal | 01-01-2002 |
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
| Bedrijven in privébezit | 7 |
|---|---|
Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Bain & Co., Inc.
Bain & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Provides strategy, marketing, organization, operations, IT and M&A consulting services | Commercial Services |
SCYNEXIS, Inc.
SCYNEXIS, Inc. Pharmaceuticals: MajorHealth Technology Develops novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections | Health Technology |
Queen's University
Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Mammoth Biosciences, Inc.
Mammoth Biosciences, Inc. Internet Software/ServicesTechnology Services Operates CRISPR-based platform for disease detection | Technology Services |
Pardes Biosciences, Inc.
Pardes Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops oral antiviral treatment for COVID-19 | Health Technology |
Kies jouw editie
Alle financiële informatie op nationaal niveau